KIT
ENSG00000157404
Target class
Kinase
Chromosome
4
Approved drugs
14
Clinical candidates (approved and in development)
34
- Approved drugs
- 14
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 34
- Chemical probe available
- Yes
- Target name
- KIT
- Gene name
- KIT proto-oncogene, receptor tyrosine kinase
- Gene symbol
- KIT
- Previous gene symbols
- PBT
- Protein name
- Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Piebald trait protein) (PBT) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (p145 c-kit) (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (CD antigen CD117)
- CD117
- SCFR
- C-Kit
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|CD molecules|Immunoglobulin like domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 46
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 44.46
- Tissue specificity (Gini)
- 0.49
- Tissue specificity (tau)
- 0.761
- KEGG gene identifiers
- hsa:3815
- Protein interaction confidence
- 0.822772
- Protein interaction partners
- 167
- R-HSA-1257604
- R-HSA-1433557
- R-HSA-1433559
- R-HSA-2219530
- R-HSA-5673001
- R-HSA-6811558
- R-HSA-8866910
- R-HSA-9669914
- R-HSA-9669917
- R-HSA-9669921
- R-HSA-9669924
- R-HSA-9669926
- R-HSA-9669929
- R-HSA-9669933
- R-HSA-9669934
- R-HSA-9669935
- R-HSA-9669936
- R-HSA-9670439
- R-HSA-9680187
- R-HSA-9856649
- R-HSA-9927418
- R-HSA-9927426
- End position
- 54740783
- Start position
- 54657267
- Chromosome
- 4
- Strand
- Forward
- [Isoform 1]: Cell membrane
- Single-pass type I membrane protein.
- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
- Single-pass type I membrane protein.
- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm . Note=Detected in the cytoplasm of spermatozoa, especially in the equatorial and subacrosomal region of the sperm head. .
- Plasma membrane
Publication evidence
- PubMed 20601678
- Tissue specificity (tau)
- 0.760917
- Expression inequality (Gini)
- 0.490256
Expression in transcripts per million
- Esophagus - Muscularis
- 44.46
- Ovary
- 36.39
- Esophagus - Gastroesophageal Junction
- 35.29
- Brain - Cerebellar Hemisphere
- 29.8
- Thyroid
- 28.09
Expression in transcripts per million
- Esophagus - Muscularis44.46
- Ovary36.39
- Esophagus - Gastroesophageal Junction35.29
- Brain - Cerebellar Hemisphere29.8
- Thyroid28.09
- Skin - Sun Exposed (Lower leg)27.76
- Brain - Cerebellum24.92
- Breast - Mammary Tissue22.34
- Minor Salivary Gland22.32
- Lung21.08
- Colon - Sigmoid20.48
- Bladder20.33
- Stomach19.2
- Skin - Not Sun Exposed (Suprapubic)19.05
- Small Intestine - Terminal Ileum15.72
- Colon - Transverse12.95
- Uterus12.01
- Adipose - Subcutaneous11.7
- Brain - Anterior cingulate cortex (BA24)11.29
- Brain - Caudate (basal ganglia)10.82
- Brain - Frontal Cortex (BA9)10.66
- Cervix - Ectocervix10.34
- Vagina9.98
- Brain - Hippocampus9.95
- Kidney - Cortex8.42
And 29 more, listed on the interactive page.
- GO:0002551
- GO:0007165
- GO:0007283
- GO:0008584
- GO:0019221
- GO:0019827
- GO:0030036
- GO:0030097
- GO:0030318
- GO:0032765
- GO:0038093
- GO:0038109
- GO:0042127
- GO:0042531
- GO:0043303
- GO:0043410
- GO:0046427
- GO:0046777
- GO:0051897
- GO:0060326
- GO:0060374
- GO:0070662
- GO:1905065
- GO:0005576
- GO:0005737
- GO:0005886
- GO:0004713
- GO:0004714
- GO:0005515
- GO:0019955
- GO:0042803
mastocytosis
Effects
- Activation/Increase/Upregulation
Studies
- clinical
PubMed 38773351cardiac disorder
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CV
PubMed 38773351heart disease
Studies
- preclinical: Important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Promotes CSC and immature cardiomyocyte differentiation; promotes homing to sites of myocardial infarction, promoting repair.
Biological samples
- cardiovascular system
PubMed 21283106Anaemia
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- blood
PubMed 38773351neutropenia
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- blood/bone marrow
PubMed 38773351haematotoxicity
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- blood
PubMed 38773351thrombocytopenia
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- blood/bone marrow
PubMed 38773351rash
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- skin
PubMed 38773351neovascularization
Effects
- Activation/Increase/Upregulation
Studies
- clinical
PubMed 38773351Carcinogenicity
Effects
- Activation/Increase/Upregulation
Studies
- clinical
PubMed 38773351
Related records
Trials (3,153)
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
- (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
- [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
- 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
- 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
- 18F-DCFBC PET/CT in Prostate Cancer
- 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Drugs (38)
- Amuvatinib Stem cell growth factor receptor inhibitor
- Avapritinib Stem cell growth factor receptor inhibitor
- Briquilimab Stem cell growth factor receptor inhibitor
- Catequentinib Stem cell growth factor receptor inhibitor
- Cediranib Stem cell growth factor receptor inhibitor
- CM-082 Stem cell growth factor receptor inhibitor
- Dasatinib anhydrous Stem cell growth factor receptor inhibitor
- Dovitinib Stem cell growth factor receptor inhibitor
- ENMD-2076 Stem cell growth factor receptor inhibitor
- Famitinib Stem cell growth factor receptor inhibitor
- Foretinib Stem cell growth factor receptor inhibitor
- Imatinib Stem cell growth factor receptor inhibitor
- Imatinib mesylate Stem cell growth factor receptor inhibitor
- Masitinib Stem cell growth factor receptor inhibitor
- Midostaurin Stem cell growth factor receptor inhibitor
- Motesanib Stem cell growth factor receptor inhibitor
- OSI-930 Stem cell growth factor receptor inhibitor
- Pazopanib Stem cell growth factor receptor inhibitor
- Pazopanib hydrochloride Stem cell growth factor receptor inhibitor
- Pexidartinib Stem cell growth factor receptor inhibitor